MAPT and Alzheimer disease: To identify whether blocking the cleavage of BIN1 by legumain could ameliorate AD pathology, we mutated amino acid 277 of endogenous BIN1 from N to A in primary neurons and adult tau P301S mice using the CRISPR/Cas9-mediated gene-editing tool.